Ribomic

4591.TPharmaceutical

Key numbers · FY ended 2026-03

Revenue¥3m+42.4% YoY Operating income−¥1.2bn—Total assets¥3.0bn-6.6% YoY EPS (basic)¥-23.07+8.5% YoY

Full financial history and reports →

Stock price4591 · View chart ↗

Open the price chart on TradingView.

Latest filings

Mon, Jun 22 · JST1 filing

16:155% STAKERibomic · Evo Fund + 1 joint holder · 29.29% → 28.68%−0.61pp

Wed, Jun 3 · JST1 filing

13:435% STAKERibomic · Evo Fund + 1 joint holder · 30.35% → 29.29%−1.06pp

Wed, May 20 · JST1 filing

15:53MATERIALRibomic · Change of independent auditor

Wed, May 13 · JST1 filing

12:335% STAKERibomic · Evo Fund + 1 joint holder · 23.93% → 30.35%+6.42pp

Tue, Apr 21 · JST1 filing

12:065% STAKERibomic · Evo Fund + 1 joint holder · 23.93% → 24.05%+0.12pp

All filings →

Major holders (5%+) · 1

Holder	Stake	Change	Filed
Evo Fund	28.68%	-0.61pp	2026-06-22

Each holder's own ratio from its most recent large-shareholding report.